1661838-94-3

1661838-94-3 structure

Name: Velagliflozin proline hydrate
Chemical Name: Velagliflozin proline hydrate
CAS Number: 1661838-94-3
Molecular Formula: C₂₈H₃₆N₂O₈
Molecular Weight: 528.59
Catalog: Signaling Pathways Membrane Transporter/Ion Channel SGLT
Create Date: 2023-05-16 10:41:11
Modify Date: 2025-09-21 21:03:08
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations[1].

Name	Velagliflozin proline hydrate

Description	Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations[1].
Related Catalog	Research Areas >> Metabolic Disease Signaling Pathways >> Membrane Transporter/Ion Channel >> SGLT
Target	SGLT2
In Vitro	Velagliflozin proline hydrate 是一种钠-葡萄糖共转运蛋白 2 (SGLT2) 抑制剂，具有抗糖尿病活性[1]。
In Vivo	Velagliflozin proline hydrate (1 mg/kg, 口服, 单剂量) 增加胆固醇、白蛋白、β -羟基丁酸 (BHB)、非酯化脂肪酸 (NEFA) 和尿葡萄糖排泄，并降低猫的呼吸交换比率[1]。 Velagliflozin proline hydrate (0.3 mg/kg; 口服; 每天 1 次, 共 18 天) 耐受性良好，可通过降低饮食非结构性碳水化合物 (NSC) 的高胰岛素反应来治疗小马的胰岛素失调和预防椎板炎[2]。
References	[1]. Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41(2):266-273. [2]. Meier A, et al. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13(9):e0203655.

Molecular Formula	C₂₈H₃₆N₂O₈
Molecular Weight	528.59